![[130] Evidence for statins in people over 70](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2021/06/130-150x150.png)
Therapeutics Letters 48, 49 and 77 summarized the effects of statins in secondary and primary prevention populations studied in randomized controlled trials (RCTs).1,2,3 This best available evidence comes from RCTs that enrolled mostly men aged … Read More
What’s New
How do you prescribe statins in the elderly?
How do you prescribe statins in the elderly? The Therapeutics Initiative produced and distributed individual prescribing Portraits on statins to patients age 70 and older (2019-2020) to approximately 5200 family doctors in BC. Eligible physicians … Read More
![[Jun 23] TI Best Evidence Webinar: Rational Treatment of Skin and Soft Tissue Infections (SSTIs)](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2021/04/Davie-Professional-Photo-113x150.jpg)
[Jun 23] TI Best Evidence Webinar: Rational Treatment of Skin and Soft Tissue Infections (SSTIs)
PRESENTER: Dr. Davie Wong is an infectious disease consultant at Royal Columbian Hospital and Eagle Ridge Hospital in Fraser Health. He has an office practice in a multidisciplinary clinic in Burnaby called Centrio Medical Specialists. He also … Read More
![[Jun 30] TI Methods Speaker Series: How to improve clinical trial reporting – insights from Europe and the US](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2021/05/Till-Bruckner.jpg)
[Jun 30] TI Methods Speaker Series: How to improve clinical trial reporting – insights from Europe and the US
TI Methods Speaker Series The TI Methods Speaker Series are offered free of charge and everyone is welcome. The event is held at noon on the last Wednesday of each month and used to take place in Rudy North Lecture Theatre (CBH 101) in the Centre … Read More
![[129] Mirtazapine: Update on efficacy, safety, dose response](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2021/05/129-150x150.png)
[129] Mirtazapine: Update on efficacy, safety, dose response
Soon after mirtazapine was licensed in Canada, a 2002 Therapeutics Letter concluded that it has “no proven efficacy or safety advantage over other antidepressant therapies”.1 Mirtazapine was approved for symptomatic relief of depressive illness and … Read More
